ArticleFrontiers in pharmacology2021

Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation.

Yuhong Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.